WALTHAM, Mass.--(BUSINESS WIRE)--
Inc. (NASDAQ: IMGN), a biotechnology
company that develops targeted anticancer therapies using its
antibody-drug conjugate (ADC) technology, today announced the
appointment of Ellie Harrison as Vice President and Chief Human
Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty
years of senior level Human Resources (HR) experience. She reports to
Daniel Junius, President and Chief Executive Officer of ImmunoGen.
“Ellie joins us in a newly created position established to ensure that –
as we progress – our talent, employee development and organizational
structures support our successful advancement to the next stages,”
commented Mr. Junius. “She brings extensive, strategic experience in HR
and will play a key role in shaping ImmunoGen as we move forward.”
Ms. Harrison has led HR functions in organizations ranging from 40 to
8,000 employees. She joins ImmunoGen from Blue Cross and Blue Shield of
Rhode Island (BCBSRI), where she was Senior Vice President of Human
Resources, with responsibility for compensation and benefits, diversity
and inclusion, talent management and acquisition, and employee
engagement and development. Prior to joining BCBSRI, Ms. Harrison was
Managing Director, Senior Human Resources Advisor at Citigroup, serving
as head of HR for multiple lines of businesses within its global
consumer banking division. Prior to joining Citigroup in 2009, Ms.
Harrison held high level HR positions of increasing responsibility at
Fidelity Investments, which she joined in 1997. Ms. Harrison’s career
has also included senior HR positions at Chubb Life America, Banc One
Asset Management Company and Healthsource, Inc. She is a graduate of the
University of Minnesota.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s
ADC technology uses a tumor-targeting engineered antibody to deliver one
of ImmunoGen's highly potent cancer-cell killing agents specifically to
tumor cells; the Company has also developed antibodies with anticancer
activity of their own. The most advanced compound with ImmunoGen’s ADC
technology is Roche’s Kadcyla®, which is marketed in the US
by Genentech and is also gaining approvals internationally. Additional
compounds are in clinical testing by ImmunoGen and through the Company’s
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademarks of Genentech, a member of
the Roche Group.
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.